Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company's lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also provides Remodulin, a treprostinil injection administered through continuous intravenous and subcutaneous infusion; and develops L606, an investigational liposomal formulation of treprostinil which is in phase III clinical trial for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). In addition, the company offers PRINT technology which allows to engineer and manufacture uniform drug particles with precise control over the size, three-dimensional geometric shape, and chemical composition of the particles. It has a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD; Vectura; The University of North Carolina at Chapel Hill; GlaxoSmithKline; Alcon Inc; and promotion Agreement with Sandoz. Liquidia Corporation was founded in 2004 and is based in Morrisville, North Carolina.
Frequently asked questions
What sector does Liquidia Corporation (LQDA) operate in?
Liquidia Corporation belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is Liquidia Corporation (LQDA) current stock price?
As of the latest data, Liquidia Corporation stock price is $72.10, with a previous close of $78.79. Liquidia Corporation lost -$6.69 in the last trading session, representing a -8.49% loss.
What is Liquidia Corporation (LQDA) current market capitalization?
Liquidia Corporation market cap is approximately 6.41 billion.
What is Liquidia Corporation (LQDA) Earnings Per Share (EPS)?
The trailing EPS is $0.17, and the forward EPS is $5.81.
What is Liquidia Corporation (LQDA) Price-to-Earnings (P/E) ratio?
Liquidia Corporation current P/E ratio is 424.12, with a forward P/E of 12.41.
What is Liquidia Corporation (LQDA) EBITDA?
Liquidia Corporation EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is 63.77 million.
Does Liquidia Corporation (LQDA) pay dividends?
No. Liquidia Corporation does not pay a dividend.
How did Liquidia Corporation (LQDA) perform in its most recent earnings report?
In the last report (March 31, 2026), Liquidia Corporation posted an EPS surprise of 28.4% and a revenue surprise of 11.27%.
When is Liquidia Corporation (LQDA) next earnings report?
Liquidia Corporation is expected to release its next earnings report on June 30, 2026.
What is Liquidia Corporation (LQDA) beta (volatility) score?
Liquidia Corporation has a beta of 0.554, indicating lower volatility than the overall market.
